Fax Server

8/27/2015 2:38:43 PM PAGE 1/001 Fax Server



Genetics Laboratories

#### BAYLOR MIRACA GENETICS LABORATORIES

2450 Holcombe Blvd - Houston, TX 77021 - 1-800-411-4363 Fax: 713-798-2787 - www.bmgl.com - genetictest@bcm.edu

Patient Name: DONOR 4622 Date of birth: M Gender: M Hospital/MR #: Accession #: Sample Type: EXT DNA Test Code: 3356 Indication: Asymptematic/Posi

### Lab Number: Family #: Date Collected: 08/10/2015 Date Received: 08/11/2015 Date Reported: 8/27/2015

Fairfax Cryobank Sendouts-Fairfax 3015 Williams Dr #110 Tel No.: 703-876-3869 Fax No: 703-698-3933 CC: Suzenne Seitz Fax # 7 CC: Harvey Stern Fax # 7

Fax# 703-698-3933 Fax# 703-698-3933

Asymptomatic/Positive Family History

#### VLCAD Deficiency ACADVL Sequence Analysis Familial Mutation/Variant Analysis

#### RESULTS:

A heterozygous c.553G>A (p.G185S) familial pathogenic variant was detected.

#### Pathogenic Variant(s)/ Mutation(s)

Nucleotide Change	Amino Acid Change	Location	Zygosity	Reference(s) / Comment(s)
c.553G>A	p.G185S	exon 7	helerozygous	PMID: 9973285

#### INTERPRETATION:

Test results should be interpreted in the context of the patient's clinical presentation and family history. Previous sequence analysis performed in this laboratory detected a heterozygous c.553G>A (p.G185S) pathogenic variant in this individual's child who had abnormal newborn screening results suggestive of VLCAD deficiency (Lab# 56744). This variant has been reported in patients with VLCAD deficiency (PMID: 9973285). We were requested to investigate this individual for the c.553G>A (p.G185S) pathogenic variant.

We received extracted DNA and the DNA sample was PCR amplified for the relevant region and then sequenced in the forward and reverse directions. Other regions of the ACADVL gene were not examined. This analysis indicates that this individual is heterozygous for the c.553G>A (p.G185S) pathogenic variant. Thus, this individual is a carrier of the familial c.553G>A (p.G185S) pathogenic variant.

Clinical correlation and genetic counseling are recommended. Targeted sequence analysis (test code 3356) is available for that this individual's relatives.

#### METHOD:

The region(s) containing the previously identified familial nutations/variants in the ACADVL (NM\_000018.2) gene were PCR any Effect and then sequenced in the forward and reverse directions using automated fluorescent dideoxy sequencing methods. Nucleotide 1 corresponds to the A of the start codon ATG.

W. Gargersto ).

William J. Cralgen, M.D., Ph.D., FACMG

ABMG Certified Chrical Geneticist and Biochemical Geneticist

Lee Jun C. Wong

Lea Jun C. Wong, Ph.D.,FACMG ABMG Cartiflod Molecular and Biochomical Geneticist Senior Laboratory Director

Assistant Laboratory Director

Fangyuan Li, M.D., Ph.D.

This leal was developed and its performance characteristics determined by Baylor Miraca Genetics Laboratories (CAP# 2003) (4/ CLIA# 4500660090). It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity isoling. This lead is used for directal purposes. It should not be regarded as investigational or for research.

Medical Director

Page 1 of 1





# Carrier Map<sup>™</sup>

### **Ordering Practice:**

Practice Code: 926 Fairfax Cryobank 3015 Williams Drive, #110, Fairfax, VA, 22031, US Physician: Suzanne Seitz Report Generated: 2015-09-08 Report Updated: 2015-09-08

### Donor 4622

### DOB: 1 Gender: Male Ethnicity: Other Procedure ID: 29150 Kit Barcode: Method: Genotyping Specimen: Sperm, #30392 Specimen Collection: 2015-08-25 Specimen Received: 2015-08-28 Specimen Analyzed: 2015-09-08

# Partner Not Tested

# SUMMARY OF RESULTS

## NO MUTATIONS IDENTIFIED

# Donor 4622 was not identified to carry any of the mutations tested.

All mutations analyzed were not detected, reducing but not eliminating your chance to be a carrier for the associated genetic diseases. A list of all the diseases and mutations you were screened for is included later in this report. The test does not screen for every possible genetic disease.

For disease information, please visit **www.recombine.com/diseases**. To speak with a Genetic Counselor, call **855.OUR.GENES**.

## o'' Male

Panel: Fairfax Cryobank Panel, Diseases Tested: 21, Mutations Tested: 382, Genes Tested: 22, Null Calls: 0

Assay performed by Reprogenetics CLIA ID: 31D1054821 Lab Technician Bo Chu

Reviewed by Pere Colls, PhD, HCLD, Lab Director



## Methods and Limitations

**Genotyping:** Genotyping is performed using the Illumina Infinium Custom HD Genotyping assay to identify mutations in >200 genes. The assay is not validated for homozygous mutations, and it is possible that individuals affected with disease may not be accurately genotyped.

**Spinal Muscular Atrophy:** Spinal Muscular Atrophy is tested for via an Identity-by-State shared haplotype comparison algorithm. Detection is limited to haplotypes within our library of known carriers of the most common mutation (deletion of Exon 7). **Limitations:** In some cases, genetic variations other than that which is being assayed may interfere with mutation detection, resulting in false-negative or false-positive results. Additional sources of error include, but are not limited to: sample contamination, sample mixup, bone marrow transplantation, blood transfusions, and technical errors.

The test does not test for all forms of genetic disease, birth defects, and intellectual disability. All results should be interpreted in the context of family history; additional evaluation may be indicated based on a history of these conditions. Additional testing may be necessary to determine mutation phase in individuals identified to carry more than one mutation in the same gene. All mutations included within the genes assayed may not be detected, and additional testing may be appropriate for some individuals.



# CarrierMap™

## Diseases & Mutations Assayed

● High Impact ● Treatment Benefits ● X-Linked ● Moderate Impact

нтхм			Mutations
	Alpha Thalassemia	10	d <sup>a</sup> Genotyping   SEA deletion, 11.1kb deletion, c.207C>A (p.N69K), c.223G>C (p.D75G), c.2T>C (p.M1T), c.207C>G (p.N69K), c.340_351delCTCCCCGCCGAG (p.L114_ E117del), c.377T>C (p.L126P), c.427T>C (p.X143Qext32), c.*+94A>G
	Beta Thalassemia	83	<b>o</b> <sup>a</sup> Genotyping   c.17_18delCT, c.20delA (p.E7Gfs), c.217insA (p.S73Kfs), c.223+702_444+342del620insAAGTAGA, c.230delC, c.25_26delAA, c.315+1G>A, c.315+2T>C, c.316-197C>T, c.316-146T>G, c.315+745C>G, c.316-1G>A, c.316-1G>C, c.316-2A>G, c.316-3C>A, c.316-3C>G, c.4delG (p.V2Cfs), c.51delC (p.K18Rfs), c.93- 21G>A, c.92+1G>A, c.92+5G>A, c.92+5G>C, c.92+5G>T, c.92+6T>C, c.93-1G>A, c.93-1G>T, c50A>C, c.a-78g, c.a-79g, c.a-81g, c.A52T (p.K18X), c.c-137g, c.c-138t, c.c-151t, c.C118T (p.Q40X), c.G169C (p.G57R), c.G295A (p.V99M), c.G34A (p.V12I), c.G415C (p.A139P), c.G47A (p.W16X), c.G48A (p.W16X), c.t-80a, c.T2C (p.M1T), c.T75A (p.G25G), c.444+111A>G, c.g-29a, c.68_74delAAGTTGG, c.G92C (p.R31T), c.27_28insG, c.92+1G>T, c.92+1G>C, c.93-15T>G, c.93-1G>C, c.112delT, c.G113A (p.W38X), c.G114A (p.W38X), c.126delC, c.444+113A>G, c.250delG, c.225delC, c.383_385delAGG (p.Q128_A129delQAinsP), c.321_322insG (p.N109fs), c.316-1G>T, c.316-2A>C, c.316-106C>T, c.287_288insA (p.L97fs), c.271G>T (p.E91X), c.203_204delTG (p.V68Afs), c.154delC (p.P52fs), c.135delC (p.F46fs), c.92+2T>A, c.92+2T>C, c.90C>T (p.G30G), c.59A>G (p.N20S), c.46delT (p.W16Gfs), c.45_46insG (p.L16fs), c.36delT (p.T13fs), c.2T>G (p.M1R), c.1A>G (p.M1V), c.c-137t, c.c-136g, c.c- 142t, c.c-140t
	Bloom Syndrome	24	of Genotyping   c.2207_2212delATCTGAinsTAGATTC (p.Y736Lfs), c.2407insT, c.557_559delCAA (p.S186X), c.1284G>A (p.W428X), c.1701G>A (p.W567X), c.1933C>T (p.Q645X), c.C2528T (p.T8431), c.C2695T (p.R899X), c.G3107T (p.C1036F), c.2923delC (p.Q975K), c.3558+1G>T, c.3875-2A>G, c.2074+2T>A, c.2343_2344dupGA (p.781EfsX), c.380delC (p.127Tfs), c.3564delC (p.1188Dfs), c.4008delG (p.1336Rfs), c.C947G (p.S316X), c.2193+1_2193+9del9, c.C1642T (p.Q548X), c.3143delA (p.1048NfsX), c.356_357delTA (p.Cys120Hisfs), c.4076+1delG, c.C3281A (p.S1094X)
• 0 0 0	Canavan Disease	8	♂ Genotyping   c.433-2A>G, c.A854C (p.E285A), c.C693A (p.Y231X), c.C914A (p.A305E), c.A71G (p.E24G), c.C654A (p.C218X), c.T2C (p.M1T), c.G79A (p.G27R)



# CarrierMap™

нтхм			Mutations
	Cystic Fibrosis	130	<b>o</b> <sup>4</sup> Genotyping   c.1029delC, 1153_1154insAT, c.1519_1521 delATC (p.507dell), c.1521_1523 delCTT (p.508 delF), c.1545_154 6 delTA (p.Y515Xfs), c.1585-1G>A, c.164+12T>C, c.1680-886A>G, c.1680-1G>A, c.1766+1G>A, c.1766+1G>T, c.1766+5G>T, c.1818 del84, c.1911 delG, c.1923 delCTCAAAACTinsA, c.1973 delGAAATTCAATCCTinsAGAAA, c.2052 delA (p.K684 fs), c.2052 insA (p.Q685fs), c.2051_2052 delAAinsG (p.K684 SfsX38), c.2174 insA, c.2014 delTT, c.2657+5G>A, c.273+1G>A, c.273+3A>C, c.274-1G>A, c.2988+1G>A, c.3039 delC, c.3140-26A>G, c.325 delTATinsG, c.3527 delC, c.3535 delACCA, c.3691 delT, c.3717+12191 C>T, c.3744 delA, c.3773_3774 insT (p.11258 fs), c.442 delA, c.489+1G>T, c.531 delT, c.579+1G>T, c.579+5G>A (IVS4+5G>A), c.803 delA (p.N268fs), c.805_80 delAT (p.1269 fs), c.933_935 delCTT (p.311 delF), c.A1645C (p.S549 R), c.A2128T (p.K710X), c.C1000T (p.R334W), c.C1013T (p.T338 l), c.C1364A (p.A455E), c.1477T (p.Q493X), c.C1572A (p.C524X), c.C1654T (p.Q552X), c.C1657T (p.R553X), c.C1721A (p.P574H), c.C2125T (p.R709X), c.C231T (p.R158X), c.C3484T (p.R1162X), c.C3497 (p.R117C), c.C3587G (p.S1196X), c.C3712T (p.R1288X), c.C3764A (p.S1255X), c.C3997 (p.R117C), c.C3587G (p.S1196X), c.C3712T (p.R1288X), c.C3764A (p.S1255X), c.G3909G (p.N1303K), c.G1040A (p.R347H), c.G1040C (p.R347P), c.G1438T (p.G480C), c.G1624T (p.G542X), c.G1646A (p.S549N), c.G1646T (p.S549), c.G1652A (p.G551D), c.G1675A (p.A559T), c.G1679C (p.R560T), c.G178T (p.E60X), c.G1865A (p.G622D), c.G254A (p.G85E), c.G271A (p.G91R), c.G274T (p.E92X), c.G3209A (p.R1070Q), c.G3266A (p.W1089X), c.G3454C (p.D1152H), c.G360A (p.R117H), c.G3311A (p.W1204X), c.G3752A (p.S1251N), c.G1845A (p.W1282X), c.G3848T (p.R1283M), c.G532A (p.G178R), c.G988T (p.G330X), c.T1090C (p.S364P), c.T3302A (p.M101K), c.f1617G (p.1206W), c.C141 (p.P51), c.G197 (p.E7X), c.G171A (p.W57X), c.3369delC (p.T1206 y, c.G3808 (p.D1270N), c.G4056C (p.Q1352H), c.C4364G (p.S1455K), c.C4003T (p.11335F), c.G2538A (p.W486X), c.C200T (p.P671), c.C4426T (p.Q1476X), c.1104+1G>A, c.1986_1989delAACT (p.T648R), c.2
$\bullet$ 0 0 0	Familial Dysautonomia	4	o <sup>e</sup> Genotyping   c.2204+6T>C, c.C2741T (p.P914L), c.G2087C (p.R696P), c.C2128T (p.Q710X)
• • • •	Familial Hyperinsulinism: Type 1: ABCC8 Related	10	ơ' Genotyping   c.3989-9G>A, c.4159_4161delTTC (p.1387delF), c.C4258T (p.R1420C), c.C4477T (p.R1493W), c.G2147T (p.G716V), c.G4055C (p.R1352P), c.T560A (p.V187D), c.4516G>A (p.E1506K), c.C2506T (p.Q836X), c.579+2T>A
	Fanconi Anemia: Type C	8	♂ Genotyping   c.456+4A>T, c.67delG, c.C37T (p.Q13X), c.C553T (p.R185X), c.T1661C (p.L554P), c.C1642T (p.R548X), c.G66A (p.W22X), c.G65A (p.W22X)
	Gaucher Disease	6	σ <sup>a</sup> Genotyping   c.84_85insG, c.A1226G (p.N409S), c.A1343T (p.D448V), c.C1504T (p.R502C), c.G1297T (p.V433L), c.G1604A (p.R535H)
	Glycogen Storage Disease: Type IA	13	o <sup>r</sup> Genotyping   c.376_377insTA, c.79delC, c.979_981delTTC (p.327delF), c.C1039T (p.Q347X), c.C247T (p.R83C), c.C724T (p.Q242X), c.G248A (p.R83H), c.G562C (p.G188R), c.G648T, c.G809T (p.G270V), c.A113T (p.D38V), c.975delG (p.L326fs), c.724delC
$\bullet$ $\circ$ $\circ$ $\circ$	Joubert Syndrome	1	♂ Genotyping   c.G35T (p.R12L)
	Maple Syrup Urine Disease: Type 1B	6	o <sup>a</sup> Genotyping   c.G1114T (p.E372X), c.G548C (p.R183P), c.G832A (p.G278S), c.C970T (p.R324X), c.G487T (p.E163X), c.C853T (p.R285X)




# Carrier Map™

нтхм			Mutations
	Maple Syrup Urine Disease: Type 3	8	ơ <sup>°</sup> Genotyping   c.104_105insA, c.G685T (p.G229C), c.A214G (p.K72E), c.A1081G (p.M361V), c.G1123A (p.E375K), c.T1178C (p.I393T), c.C1463T (p.P488L), c.A1483G (p.R495G)
$\bullet$ 0 0 0	Mucolipidosis: Type IV	4	♂ Genotyping   c.406-2A>G, c.G1084T (p.D362Y), c.C304T (p.R102X), c.244delC (p.L82fsX)
000	Nemaline Myopathy: NEB Related	1	o <sup>a</sup> Genotyping   c.7434_7536del2502bp
$\bullet$ $\circ$ $\circ$ $\circ$	Niemann-Pick Disease: Type A	6	♂ Genotyping   c.996delC, c.G1493T (p.R498L), c.T911C (p.L304P), c.C1267T (p.H423Y), c.G1734C (p.K578N), c.1493G>A (p.R498H)
	Spinal Muscular Atrophy: SMN1 Linked	19	o <sup>e</sup> Genotyping   DEL EXON 7, c.22_23insA, c.43C>T (p.Q15X), c.91_92insT, c.305G>A (p.W102X), c.400G>A (p.E134K), c.439_443delGAAGT, c.558delA, c.585_586insT, c.683T>A (p.L228X), c.734C>T (p.P245L), c.768_778dupTGCTGATGCTT, c.815A>G (p.Y272C), c.821C>T (p.T274I), c.823G>A (p.G275S), c.834+2T>G, c.835-18_835- 12delCCTTTAT, c.835G>T, c.836G>T
	Tay-Sachs Disease	30	<b>σ</b> <sup>*</sup> Genotyping   c.1073+1G>A, c.1277_1278insTATC, c.1421+1G>C, c.805+1G>A, c.C532T (p.R178C), c.G533A (p.R178H), c.G805A (p.G269S), c.C1510T (p.R504C), c.G1496A (p.R499H), c.G509A (p.R170Q), c.A1003T (p.I335F), c.910_912delTTC (p.305delF), c.G749A (p.G250D), c.T632C (p.F211S), c.C629T (p.S210F), c.613delC, c.A611G (p.H204R), c.G598A (p.V200M), c.A590C (p.K197T), c.571-1G>T, c.C540G (p.Y180X), c.T538C (p.Y180H), c.G533T (p.R178L), c.C508T (p.R170W), c.C409T (p.R137X), c.T380G (p.L127R), c.346+1G>C, c.T116G (p.L39R), c.G78A (p.W26X), c.A1G (p.M1V)
$\bullet$ 0 0 0	Usher Syndrome: Type 1F	6	♂ Genotyping   c.C733T (p.R245X), c.2067C>A (p.Y684X), c.C7T (p.R3X), c.C1942T (p.R648X), c.2800C>T (p.R934X), c.4272delA (p.L1425fs)
$\bullet$ 0 0 0	Usher Syndrome: Type 3	4	Ф <sup>®</sup> Genotyping   c.T144G (p.N48K), c.T359A (p.M120K), c.300T>G (p.Y176X), c.C634T (p.Q212X)
000	Walker-Warburg Syndrome	1	♂ Genotyping   c.1167insA (p.F390fs)

PAGE: 1	2006		2		
LABORATORY REPC T	IKONMAIL		$\langle \rangle$	Sonora Que	st
12738 FAIRFAX CRYOBANK-			24 7	A Subidiary of Laboratory Sciences of Ariz	5
	ł	Collected Date	ר י	Received Date 0/01/2012 1847	Collection Time 1330
		Reported Date		Other I.D.	Fasting
REQUISITION NO. PHYSICIAN		10/05/2012		Curio, no.	U
127380000000086	DOB	AGE	SEX	PATIENT ID	ACCESSION NO.
ID,4622 DONOR			М		
REQUESTS RES * Previously R		JT OF RANGE RESULTS 1: 10/04/201		REFERENCE RANGE 8:13PM *	UNITS FN
CBC W/DIFF,W/PLT					
WBC	6.2			4.0-11.0	k/mm3
	5.04			4.30-6.00	m/mm3
	L5.4 15.1			13.0-18.0 40.0-53.0	g/dL %
	15.1 90			40.0-53.0 78-100	fL
	90 30.6			27.0-34.0	pg
	30.6 34.1			31.0-37.0	g/dL
	12.9			12.1-18.2	%
	11.9			36.0-55.0	fL
PLATELET COUNT 22				130-450	k/mm3
	10.8			7.5-14.0	fL
SEGMENTED NEUTROPHILS 6	50 <b>दि</b>	NTERE	n	40-85	00
LYMPHOCYTES 2	27 2,	(11 2.7.13)	IJ	10-45	00
MONOCYTES	6		2	3-15	00
EOSINOPHILS	7			0 - 7	00
BASOPHILS	1			0-2	% 1 /
	3.7			1.6-9.3	k/uL
ABSOLUTE LYMPHOCYTE	1.7			0.6-5.5	k/uL
ABSOLUTE MONOCYTE	0.3			0.1-1.6	k/uL
ABSOLUTE EOSINOPHIL	0.4			0.0-0.7	k/uL
ABSOLUTE BASOPHIL	0.0			0.0-0.2	k/uL
and the set of the second s	Automated			eer n. taalego	
	22			10-50	
CHOLESTEROL 19				<200	mg/dL
	19			2-60	IU/L
	O Negative				
Sonora Quest Laboratories no longer performs "weak D" or "Du" testing routinely. It is no longer a regulatory requirement, nor is it recommended by the American Association of Blood Banks (AABB), except in testing of donor units. Supplemental testing for weak D/Du Testing, may be performed for an additional charge by request. Please call the Client Services Department at 602-685-5050 and request test number 102317.					
HEMOGLOBINOPATHY EVALUATION					
RED BLOOD CELL COUNT	5.10			4.30-6.00	
HEMOGLOBIN	15.4			13.5-17.0	
MCV	90			78-100	fL G
RDW	13.2			11.0-16.0	% G
ID,4622 DONOR - E90278930 - RH	EPRINT REPC	)RT		CONTINUED	ON PAGE 2

PAGE: 2 LABORATORY	2006 2006	-1 2		
12738 FAIRFAX CRYOBAN			Sonora Que	st
		Collected Date	A Subsidiary of Laboratory Sciences of Ariza	ona
		Collected Date	Received Date 0/01/2012 1847	Collection Time 1330
EQUISITION NO. PHYSICIAN		Reported Date	Other I.D.	Fasting U
127380000000086	000			
ID,4622 DONOR	DOB	AGE SEX	PATIENT ID	ACCESSION NO.
REQUESTS	RESULTS	DUT OF RANGE RESULTS	REFERENCE RANGE	UNITS FN
HEMOGLOBIN A HEMOGLOBIN A2 PATHOLOGIST INTERPREI	97.3 2.7 CATION		94.5-98.5 1.8-3.5	% G % G G
Normal phenotype.	Reviewed by Dr. Lou	uis Novoa-Taka	ra	
Evaluation perform Gel electrophoresi	ned by High Performa s performed only wh	ance Liquid Chr nen indicated.	romatography (H	PLC).
hemoglobins such a	Evaluation examines s S, C, and E as we s. Many, but not al	ell as most oth	ner less common	10
If, in spite of no abnormality persis	ormal findings, a cl ts please contact t	linical suspici the laboratory.	on of a hemogl	obin
RDWSD	43.4		36.0-55.0	% G
TESTS ORDERED: AST CBC	;CHOLESTEROL;ALT;BI W/DIFF,W/PLT;HEMOC	LOOD GROUP AND GLOBINOPATHY EV	RH TYPE ALUATION	
Unless otherwi	se noted,			
all testing perf	ormed at: Sonora Q 1255 Wes Tempe, A	Quest Laborator st Washington S AZ 85281 5000 or 800.76	Street	
= Test perf	1111 E.	McDowell Road AZ 85006	Medical Center	
			ENTERE (122-7/13	

END OF REPORT. PRINTED 10/05/2012 @ 08:31:24 AM ID,4622 DONOR - E90278930 - REPRINT REPORT



#### INTERPRETATION

Normal male karyotype

No clonal numerical or structural abnormalities were identified. This normal cytogenetic result does not exclude the possibility of the presence of subtle rearrangements beyond the technical limits of detection with this test.


Comments

Wayne S. Stanley, Ph.D., FACMG

Clinical Cytogeneticist

10	116	12	
		Date	

## Genetics and IVF Preimplantation Genetics Laboratory



Case: 12-143CG Slide: A1 Cell: 7

